Tommy Li

6PUBLICATIONS
19CO-AUTHORS
Molecular targetsHaematological tumoursPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 28, 2026
An In Vitro Quantitative Systems Pharmacology Platform for Characterizing CD3-Bispecific Antibody-Mediated T-Cell Activation and Tumor Cell Cytotoxicity.

|Jul 07, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

|May 15, 2026
Model-Informed Dosing Strategies for Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma.

|Feb 12, 2025
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma.

Tommy Li, Leonid Gibiansky, Apurvasena Parikh

|Sep 19, 2024
Industry Perspective on First-in-Human and Clinical Pharmacology Strategies to Support Clinical Development of T-Cell Engaging Bispecific Antibodies for Cancer Therapy.

Prathap Nagaraja Shastri, Nirav Shah, Martin Lechmann

|Aug 23, 2022
Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.

Tommy Li, Ida H Hiemstra, Christopher Chiu

Pageof 1

Frequent Collaborators

3 joint publications

Steven Xu

2 joint publications

Christopher W Chiu

2 joint publications

Yanguang Cao

2 joint publications

Apurvasena Parikh